. Author manuscript; available in PMC: 2015 Nov 1.

Published in final edited form as: Liver Int. 2014 Mar 7;34(10):1488–1495. doi: 10.1111/liv.12492

Table 2.

Associations at HLA-B in small duct primary sclerosing cholangitis and controls

	Scandinavia		UK		US
	Small duct PSC 2n=86	Controls 2n=730	Small duct PSC 2n=51	Controls 2n=1200	Small duct PSC 2n=32	Controls 2n=237	Overall meta-analysis
HLA-B^*	Alleles %	Alleles %	Alleles %	Alleles %	Alleles %	Alleles %	OR	95% CI	p _uncorrected
5	10	4	4	5	3	5	1.69	0.90–3.17	0.11
7	19	16	12	15	9	12	0.97	0.62–1.52	0.91
8	19	13	16	13	28	13	1.62	1.08–2.44	0.02
12	15	15	16	19	9	15	0.84	0.54–1.32	0.45
13	3	1	0	2	6	2	2.32^a	0.90–5.98	0.08
14	5	3	4	4	6	5	1.37	0.64–2.93	0.41
15	6	11	8	7	9	4	0.85	0.46–1.57	0.61
16	0	2	0	1	0	1	0.50^a	0.10–2.57	0.41
17	0	3	12	4	0	6	0.67^ab	0.05–9.04	0.76
18	5	2	4	4	0	5	1.21^a	0.53–2.76	0.65
21	2	2	4	2	3	4	1.22	0.48–3.11	0.68
22	0	1	2	3	0	2	0.69^a	0.16–2.90	0.61
27	2	8	4	4	0	4	0.43^a	0.17–1.11	0.08
35	3	8	6	6	13	9	0.78	0.40–1.51	0.46
37	1	2	4	1	0	2	1.35^a	0.44–4.10	0.60
3901	2	0	2	1	3	1	4.23^a	1.40–12.78	0.01^c
40	6	10	4	7	6	7	0.59	0.29–1.18	0.13

Only alleles with frequency ≥ 1 % in at least one of the groups are presented. CI: confidence interval; OR: odds ratio; PSC: primary sclerosing cholangitis.

Zero cell correction performed by adding 0.5.

Significant test of heterogeneity, p (X²2_df) =0.01, random effects model used.

Bonferroni corrected p-value; 0.24.

HLA-B presented with serotype nomenclature, i.e. B5 corresponds to HLA-B*51:XX and B*52:XX alleles, B7 to B*07:XX, B8 to B*08:XX, B12 to B*44:XX and B*45:XX, B13 to B*13:XX, B14 to B*14:XX, B15 to B*15:XX, B16 to B*38:XX and B*39:XX, B17 to B*57:XX and B*58:XX, B18 to B*18:XX, B21 to B*49:XX and B*50:XX, B22 to B*54:XX, B*55:XX and B*56:XX, B27 to B*27:XX, B35 to B*35:XX, B37 to B*37:XX, B3901 to B*39:01, B40 to B*40:XX.